Sorbent's fluid overload drug enters midstage trial

04/15/2013 | Pharmaceutical Business Review Online

Sorbent Therapeutics initiated a Phase IIb study to assess the safety and efficacy of its experimental drug CLP-1001 in treating signs and symptoms of fluid overload in 250 patients with heart failure. CLP-1001 is a non-absorbed oral polymer that targets excess sodium and fluid in the gastrointestinal tract.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL